BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Euronext Paris 13:54:04 30/04/2024 BST | ||
| 5.712 EUR | +0.62% |
|
| Current month | +35.88% | ||
| 1 month | +35.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 5.712 | +0.62% | 68 |
| 29/04/24 | 5.677 | -0.63% | 110 |
| 26/04/24 | 5.713 | +1.17% | 108 |
| 25/04/24 | 5.647 | +15.69% | 110 |
| 24/04/24 | 4.881 | +2.35% | 96 |
Real-time Euronext Paris
Last update April 30, 2024 at 01:54 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| B7S8Z | |
| ISIN | DE000CL4JXQ3 |
| Date issued | 20/03/2020 |
| Strike | 7,207 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.397 € |
|---|---|
| Lowest since issue | 0.71 € |
| Spread | 0.006 € |
| Spread % | 0.10% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
150.9
USD
Average target price
164.3
USD
Spread / Average Target
+8.86%
- Stock Market
- Certificates
- B7S8Z Certificat
